Bioavailability of Cariban® Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy

被引：0
|
作者：
Paula Saz-Leal
Laura Zamorano-Domínguez
Jesús Frías
Pedro Guerra
Marc Saura-Valls
Ramón Roca-Juanes
Joaquín Nebot-Troyano
Eva García-Aguilar
Tatiana Vilchez
Katia Urso
机构：
[1] ITF Research Pharma S.L.U.,Medical Department
[2] ITF Research Pharma S.L.U.,R&D Department
[3] IdiPAZ,Clinical Pharmacology Department, La Paz University Hospital, School of Medicine
[4] Autonomous University of Madrid,undefined
[5] Inibsa Ginecologia S.A,undefined
来源：
Drugs in R&D | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 195
页数：10
相关论文
共 42 条
  • [31] The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
    Vaswani, Bharat
    Dattatreya, Palanki S.
    Barkate, Hanmant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Jadhav, Amit Y.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [32] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    Gralla, R. J.
    Bosnjak, S. M.
    Hontsa, A.
    Balser, C.
    Rizzi, G.
    Rossi, G.
    Borroni, M. E.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339
  • [33] Effectiveness of NEPA, an oral fixed-dose combination of NEtupitant and PAlonosetron in the prevention of chemotherapy-induced nausea-vomiting in patient receiving highly emetogenic chemotherapy regimens.
    Jadhav, Amit Y.
    Gupta, Sudeep
    Biswas, Ghanashyam
    Chandrakanth, M., V
    Dattatreya, Palanki Satya
    Thomas, Boben
    Gupta, Sumant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Barkate, Hanmant B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.
    Jordan, Karin
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] An Open-Label, Randomized, Crossover Study to Compare Pharmacokinetics of Fixed-Dose Combination vs. Free-Dose Combination of Dapagliflozin and Metformin Modified Release in Russian Population
    Khomitskaya, Yunona
    Tikhonova, Nadezhda
    Erofeeva, Svetlana
    Holmes, Victoria
    Dayton, Brian
    Davies, Nigel
    Boulton, David
    Tang, Weifeng
    DIABETES, 2017, 66 : A316 - A316
  • [36] A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    Aapro, M.
    Rugo, H.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Bondarenko, I.
    Sarosiek, T.
    Oprean, C.
    Cardona-Huerta, S.
    Lorusso, V.
    Karthaus, M.
    Schwartzberg, L.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1328 - 1333
  • [37] NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
    Rugo, H. S.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Bondarenko, I.
    Sarosiek, T. J.
    Aapro, M. S.
    CANCER RESEARCH, 2013, 73
  • [38] Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)
    Jahn, P.
    Jordan, K.
    Rizzi, G.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S20 - S21
  • [39] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [40] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345